Free Trial

Navidea Biopharmaceuticals (NAVB) Competitors

Navidea Biopharmaceuticals logo
$0.0001 0.00 (-50.00%)
As of 07/17/2025 09:30 AM Eastern

NAVB vs. SCPS, EVLO, CMRA, GNCAQ, GNCA, AMPE, ARDS, STAB, EFTR, and HSTO

Should you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Ampio Pharmaceuticals (AMPE), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), eFFECTOR Therapeutics (EFTR), and Histogen (HSTO). These companies are all part of the "pharmaceutical products" industry.

Navidea Biopharmaceuticals vs. Its Competitors

Scopus BioPharma (NASDAQ:SCPS) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

Scopus BioPharma has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Navidea Biopharmaceuticals Neutral

Scopus BioPharma has higher earnings, but lower revenue than Navidea Biopharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Navidea Biopharmaceuticals$8.13K1.23-$15.18MN/AN/A

Summary

Navidea Biopharmaceuticals beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

Get Navidea Biopharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NAVB vs. The Competition

MetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE Exchange
Market Cap$10K$17.96M$5.54B$20.85B
Dividend YieldN/AN/A3.75%3.65%
P/E RatioN/AN/A21.0126.34
Price / Sales1.2318.41433.8159.22
Price / CashN/AN/A36.1622.29
Price / BookN/A0.018.124.66
Net Income-$15.18M-$15.34M$3.25B$994.58M
7 Day PerformanceN/A1.09%0.97%-0.29%
1 Month PerformanceN/A0.57%7.36%4.91%
1 Year PerformanceN/A3.05%31.31%10.53%

Navidea Biopharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NAVB
Navidea Biopharmaceuticals
N/A$0.00
-50.0%
N/A-90.0%$10K$8.13K0.0010
SCPS
Scopus BioPharma
N/A$0.00
flat
N/AN/A$13KN/A0.009
EVLO
Evelo Biosciences
N/A$0.00
flat
N/AN/A$9KN/A0.00120
CMRA
Comera Life Sciences
N/A$0.00
flat
N/AN/A$6K$1.00M0.002
GNCAQ
Genocea Biosciences
N/AN/AN/AN/A$6KN/A0.0070
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91M0.0070
AMPE
Ampio Pharmaceuticals
N/A$0.00
+3,900.0%
N/A-88.9%$5KN/A0.0020Gap Up
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat
N/AN/A$5KN/A0.0030
STAB
Statera Biopharma
N/A$0.00
flat
N/A-83.3%$5KN/A0.0020
EFTR
eFFECTOR Therapeutics
0.0726 of 5 stars
$0.00
-33.3%
N/A-99.6%$1KN/A0.0010
HSTO
Histogen
N/A$0.00
flat
N/A-84.9%$1K$19K0.0020Gap Down

Related Companies and Tools


This page (NYSE:NAVB) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners